Research ExplorerPublicationsInteraction of PVR/PVRL2 with TIGIT/DNAM-1 as a novel immune...

Interaction of PVR/PVRL2 with TIGIT/DNAM-1 as a novel immune checkpoint axis and therapeutic target in cancer

Standard

Interaction of PVR/PVRL2 with TIGIT/DNAM-1 as a novel immune checkpoint axis and therapeutic target in cancer. / Stamm, Hauke; Wellbrock, Jasmin; Fiedler, Walter.

In: MAMM GENOME, Vol. 29, No. 11-12, 12.2018, p. 694-702.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

Stamm, H, Wellbrock, J & Fiedler, W 2018, 'Interaction of PVR/PVRL2 with TIGIT/DNAM-1 as a novel immune checkpoint axis and therapeutic target in cancer', MAMM GENOME, vol. 29, no. 11-12, pp. 694-702. https://doi.org/10.1007/s00335-018-9770-7

APA

Stamm, H., Wellbrock, J., & Fiedler, W. (2018). Interaction of PVR/PVRL2 with TIGIT/DNAM-1 as a novel immune checkpoint axis and therapeutic target in cancer. MAMM GENOME, 29(11-12), 694-702. https://doi.org/10.1007/s00335-018-9770-7

Vancouver

Stamm H, Wellbrock J, Fiedler W. Interaction of PVR/PVRL2 with TIGIT/DNAM-1 as a novel immune checkpoint axis and therapeutic target in cancer. MAMM GENOME. 2018 Dec;29(11-12):694-702. https://doi.org/10.1007/s00335-018-9770-7

Bibtex

@article{af4a721f0531433891180637dae60034,
title = "Interaction of PVR/PVRL2 with TIGIT/DNAM-1 as a novel immune checkpoint axis and therapeutic target in cancer",
abstract = "Avoiding immune surveillance and inducing a tumor-promoting inflammatory milieu found entry into the new generation of the hallmarks of cancer. Cancer cells hijack immune mechanisms which physiologically protect the body from the development of autoimmune diseases and excessive tissue damage during inflammation by downregulating immune responses. This is frequently achieved by upregulation of immune checkpoints. Therefore, the blocking of immune checkpoint ligand-receptor interactions can reinstall the immune systems capability to fight cancer cells as shown for CTLA4 and PD-1 inhibitors in a clinical setting. Newly described checkpoint antigens are currently under investigation in cancer immunotherapy. Preclinical data emphasize the immune checkpoint axis TIGIT-PVR/PVRL2 as very promising target. This axis includes additional receptors such as DNAM-1, CD96, and CD112R. In this review, we discuss the recent findings of the relevance of this complex receptor ligand system in hematologic and solid cancers. Emphasis is also laid on the discussion of potential combinations with other immunotherapeutic approaches.",
keywords = "Journal Article, Review",
author = "Hauke Stamm and Jasmin Wellbrock and Walter Fiedler",
year = "2018",
month = dec,
doi = "10.1007/s00335-018-9770-7",
language = "English",
volume = "29",
pages = "694--702",
journal = "MAMM GENOME",
issn = "0938-8990",
publisher = "Springer New York",
number = "11-12",

}

RIS

TY - JOUR

T1 - Interaction of PVR/PVRL2 with TIGIT/DNAM-1 as a novel immune checkpoint axis and therapeutic target in cancer

AU - Stamm, Hauke

AU - Wellbrock, Jasmin

AU - Fiedler, Walter

PY - 2018/12

Y1 - 2018/12

N2 - Avoiding immune surveillance and inducing a tumor-promoting inflammatory milieu found entry into the new generation of the hallmarks of cancer. Cancer cells hijack immune mechanisms which physiologically protect the body from the development of autoimmune diseases and excessive tissue damage during inflammation by downregulating immune responses. This is frequently achieved by upregulation of immune checkpoints. Therefore, the blocking of immune checkpoint ligand-receptor interactions can reinstall the immune systems capability to fight cancer cells as shown for CTLA4 and PD-1 inhibitors in a clinical setting. Newly described checkpoint antigens are currently under investigation in cancer immunotherapy. Preclinical data emphasize the immune checkpoint axis TIGIT-PVR/PVRL2 as very promising target. This axis includes additional receptors such as DNAM-1, CD96, and CD112R. In this review, we discuss the recent findings of the relevance of this complex receptor ligand system in hematologic and solid cancers. Emphasis is also laid on the discussion of potential combinations with other immunotherapeutic approaches.

AB - Avoiding immune surveillance and inducing a tumor-promoting inflammatory milieu found entry into the new generation of the hallmarks of cancer. Cancer cells hijack immune mechanisms which physiologically protect the body from the development of autoimmune diseases and excessive tissue damage during inflammation by downregulating immune responses. This is frequently achieved by upregulation of immune checkpoints. Therefore, the blocking of immune checkpoint ligand-receptor interactions can reinstall the immune systems capability to fight cancer cells as shown for CTLA4 and PD-1 inhibitors in a clinical setting. Newly described checkpoint antigens are currently under investigation in cancer immunotherapy. Preclinical data emphasize the immune checkpoint axis TIGIT-PVR/PVRL2 as very promising target. This axis includes additional receptors such as DNAM-1, CD96, and CD112R. In this review, we discuss the recent findings of the relevance of this complex receptor ligand system in hematologic and solid cancers. Emphasis is also laid on the discussion of potential combinations with other immunotherapeutic approaches.

KW - Journal Article

KW - Review

U2 - 10.1007/s00335-018-9770-7

DO - 10.1007/s00335-018-9770-7

M3 - SCORING: Review article

C2 - 30132062

VL - 29

SP - 694

EP - 702

JO - MAMM GENOME

JF - MAMM GENOME

SN - 0938-8990

IS - 11-12

ER -